"sustained release formulation" is correct and usable in written English.
You can use this phrase in any context when referring to the use of a formulation for extended release of a drug or other chemical compound. For example: "The new sustained release formulation of the drug will provide better, more consistent results over time."
This encapsulation has significantly improved the efficacy of the drug in a rat model of PTOA and provided supporting evidence to the utility of formulating IL-1 ra as a sustained release formulation for intra-articular delivery.
The dissolution of diclofenac from sustained release formulation was pH-dependent.
This progression began in 1952 with the introduction of the first sustained release formulation.
The in vivo pharmacokinetic parameters of the optimized formulation were compared with the marketed sustained release formulation of atenolol (Aten®).
MitoGel is a novel sustained release formulation of mitomycin C (MMC) based on RTGel, a proprietary thermosensitive hydrogel technology.
A method for predicting dissolution profiles of directly compressed tablets for a fixed sustained release formulation manufactured in a continuous direct compaction (CDC) system is presented.
Therefore, NaAL has been studied for preparing sustained release formulations in pharmaceutical technology.
Non-site-specific delivery of mesalamine is the major drawback of immediate release formulations, whereas sustained release formulations lack "loading dose" when the target site is reached.
The aim of this study was to investigate the effect of formulation on the pharmacokinetics of diclofenac in two sustained release formulations (formulation A and Voltaren SR®) after oral delivery.
While the in vitro release characteristics of these two sustained release formulations were broadly different, the plasma rhVEGF165 concentration time profiles following hind-limb intramuscular (IM) injection of these formulations in non-compromised rats revealed similar in vivo pharmacokinetics.
Certain issues with the use of particles of chitosan (Ch) cross-linked with tripolyphosphate (TPP) in sustained release formulations include inefficient drug loading, burst drug release, and incomplete drug release.
